FrancophonIA/ELRC3.0 huggingface dataset:
English: • 800 micrograms fentanyl (as citrate)
Estonian: • 800 mikrogrammi fentanüüli (tsitraadina)
English: stomach pain, uncomfortable stomach, indigestion, toothache, oral thrush
Estonian: ebamugavustunne maos, seedehäire, hambavalu, suusoor
English: Anaphylaxis and hypersensitivity
Estonian: Anafülaksia ja ülitundlikkus
English: Effentora 100 micrograms buccal tablets EU/1/08/441/001-002
Estonian: Effentora 100 mikrogrammi bukaaltabletid EU/1/08/441/001-002
English: Effentora 200 micrograms buccal tablets Each buccal tablet contains 200 micrograms fentanyl (as citrate).
Estonian: Effentora 200 mikrogrammi bukaaltabletid Iga bukaaltablett sisaldab 200 mikrogrammi fentanüüli (tsitraadina).
English: Effentora 200 micrograms buccal tablets EU/1/08/441/003-004
Estonian: Effentora 200 mikrogrammi bukaaltabletid EU/1/08/441/003-004
English: • 400 micrograms fentanyl (as citrate)
Estonian: • 400 mikrogrammi fentanüüli (tsitraadina)
English: Effentora 600 micrograms buccal tablets EU/1/08/441/007-008
Estonian: Effentora 600 mikrogrammi bukaaltabletid EU/1/08/441/007-008
English: Urinary retention
Estonian: Uriiniretentsioon
English: Effentora 600 micrograms buccal tablets Each buccal tablet contains 600 micrograms fentanyl (as citrate).
Estonian: Effentora 600 mikrogrammi bukaaltabletid Iga bukaaltablett sisaldab 600 mikrogrammi fentanüüli (tsitraadina).
English: • 600 micrograms fentanyl (as citrate)
Estonian: • 600 mikrogrammi fentanüüli (tsitraadina)
English: Each buccal tablet contains 800 micrograms fentanyl (as citrate)
Estonian: Iga bukaaltablett sisaldab 800 mikrogrammi fentanüüli (tsitraadina)
English: Effentora 400 micrograms buccal tablets Each buccal tablet contains 400 micrograms fentanyl (as citrate).
Estonian: Effentora 400 mikrogrammi bukaaltabletid Iga bukaaltablett sisaldab 400 mikrogrammi fentanüüli (tsitraadina).
English: • one or more of the following problems in the mouth: ulcer, loss of sensation, discomfort, unusual colour, soft tissue disorder, tongue disorder, painful or blistered or ulcerated tongue, gum pain, chapped lips, tooth disorder
Estonian: • külm higi, näo turse, üldine kihelus, juuste väljalangemine, lihaste tõmblused, lihasnõrkus, halb enesetunne, ebamugavustunne rindkeres, janu, külmatunne, kuumatunne, urineerimishäired
English: Each buccal tablet contains 400 micrograms fentanyl (as citrate)
Estonian: Iga bukaaltablett sisaldab 400 mikrogrammi fentanüüli (tsitraadina)
English: Each buccal tablet contains 200 micrograms fentanyl (as citrate)
Estonian: Iga bukaaltablett sisaldab 200 mikrogrammi fentanüüli (tsitraadina)
English: Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “8”.
Estonian: Effentora 800 mikrogrammi bukaaltabletid Lame, valge, ümar, kaldservadega tablett, ühele küljele pressitud “C” ja teisele küljele “8”.
English: Each buccal tablet contains 600 micrograms fentanyl (as citrate)
Estonian: Iga bukaaltablett sisaldab 600 mikrogrammi fentanüüli (tsitraadina)
English: Oral pustule
Estonian: Suu pustulid
English: • 200 micrograms fentanyl (as citrate)
Estonian: • 200 mikrogrammi fentanüüli (tsitraadina)
English: Ελλάδα
Estonian: Aeg-ajalt
English: Effentora 100 micrograms buccal tablets Each buccal tablet contains 100 micrograms fentanyl (as citrate).
Estonian: Effentora 100 mikrogrammi bukaaltabletid Iga bukaaltablett sisaldab 100 mikrogrammi fentanüüli (tsitraadina).
English: 400 mcg EFFENTORA
Estonian: 400 µg EFFENTORA
English: Dyspnoea Pharyngolaryngeal pain
Estonian: Tahhükardia Bradükardia
English: Effentora 800 micrograms buccal tablets
Estonian: Effentora 800 mikrogrammi bukaaltabletid Fentanüül
English: Each buccal tablet contains 100 micrograms fentanyl (as citrate)
Estonian: Iga bukaaltablett sisaldab 100 mikrogrammi fentanüüli (tsitraadina)
English: • 100 micrograms fentanyl (as citrate)
Estonian: • 100 mikrogrammi fentanüüli (tsitraadina)
English: Cognitive disorder Motor dysfunction
Estonian: Motoorsed häired
English: Effentora 600 micrograms buccal tablets
Estonian: Effentora 600 mikrogrammi bukaaltabletid Fentanüül
English: Nausea, vomiting, anorexia, fatigue, weakness, dizziness and low blood pressure Together these symptoms may be a sign of a potentially life-threatening condition called adrenal insufficiency.
Estonian: iiveldus, oksendamine, anoreksia, väsimus, nõrkus, pearinglus ja madal vererõhk.
English: Effentora 200 micrograms buccal tablets
Estonian: Effentora 200 mikrogrammi bukaaltabletid Fentanüül
English: redness, swelling or spots
Estonian: • lihasvalu, seljavalu
English: Effentora 400 micrograms buccal tablets
Estonian: Effentora 400 mikrogrammi bukaaltablett Fentanüül
English: Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “6”.
Estonian: Effentora 600 mikrogrammi bukaaltabletid Lame, valge, ümar, kaldservadega tablett, ühele küljele pressitud “C” ja teisele küljele “6”.
English: Effentora 100 micrograms buccal tablets Fentanyl
Estonian: Effentora 100 mikrogrammi bukaaltabletid Fentanüül
English: Dose readjustment
Estonian: Annuse korduv kohandamine
English: Effentora 400 micrograms buccal tablets Fentanyl
Estonian: Effentora 400 mikrogrammi bukaaltabletid Fentanüül
English: Taking the medicine
Estonian: Ravimi kasutamine
English: Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “2”.
Estonian: Effentora 200 mikrogrammi bukaaltabletid Lame, valge, ümar, kaldservadega tablett, ühele küljele pressitud “C” ja teisele küljele “2”.
English: Onychorrhexis
Estonian: Manustamiseviis
English: Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “4”.
Estonian: Effentora 400 mikrogrammi bukaaltabletid Lame, valge, ümar, kaldservadega tablett, ühele küljele pressitud “C” ja teisele küljele “4”.
English: Effentora 100 micrograms buccal tablets
Estonian: Effentora 100 mikrogrammi bukaaltablett Fentanüül
English: Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “1”.
Estonian: Bukaaltabletid on lamedad, ümarad, kaldservadega tabletid, ühele küljele pressitud “C” ja teisele
English: Musculoskel etal and connective tissue disorders
Estonian: Lihas-skeleti ja sidekoe kahjustused
English: • muscle pain, back pain
Estonian: • pearinglus, peavalu
English: Peel
Estonian: Ravi
English: Feeling cold Feeling hot
Estonian: Külmatunne Kuumatunne
English: Place in buccal cavity.
Estonian: Oromukosaalne.Asetada põseõõnde.
English: Posology
Estonian: Onühhoreksia
English: Content (concentration)
Estonian: Ravimvorm Manustamistee Pakendi iseloomustus Pakendi sisu (kontsentratsioon)
English: The application was at day 180 when the company withdrew.
Estonian: Taotluse menetlemine oli 180. päeva seisus, kui ettevõte taotluse tagasi võttis.
English: International non-proprietary name (INN): hyaluronidase (ovine)
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): (lamba) hüaluronidaas
English: What is Vitragan?
Estonian: Mis on Vitragan?
English: The Committee was also concerned over the safety of the medicine and the consistency of the medicine between batches.
Estonian: Komiteele valmistas muret ka ravimi ohutus ja eri partiide ühtlane kvaliteet.
English: On 25 April 2007, ISTA Pharma Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Vitragan, for the treatment of vitreous haemorrhage.
Estonian: 25. aprillil 2007 teavitas ISTA Pharma Limited ametlikult inimtervishoius kasutatavate ravimite komiteed oma soovist võtta tagasi müügiloa taotlus ravimile Vitragan klaaskeha veritsemise raviks.
English: This was intended to improve vision and to help doctors in their diagnosis of underlying problems in the retina (the light-sensitive surface at the back of the eye).
Estonian: See pidanuks parandama nägemist ning aitama arstidel diagnoosida tõsisemaid probleeme võrkkestas (valgustundlik pind silma tagaosas).
English: The company also presented the results of two main studies involving 1,306 patients with vitreous haemorrhage, where the effects of a single injection of Vitragan were compared with those of placebo (a dummy treatment).
Estonian: Ettevõte esitas ka kahe põhiuuringu tulemused, milles osales 1306 klaaskeha veritsemisega patsienti ja milles võrreldi ühekordse Vitragani süsti toimet platseeboga (näiv ravim).
English: Once the company has supplied responses to the questions, the CHMP reviews them and may, before giving an opinion, ask any remaining questions at day 180.
Estonian: Pärast seda, kui ettevõte on esitatud küsimustele vastanud, vaatab inimtervishoius kasutatavate ravimite komitee need läbi ning võib enne oma arvamuse väljendamist esitada ettevõttele täiendavaid küsimusi (180. päeval).
English: When the acid is broken down, the vitreous humour turns from a jelly into a liquid, allowing cells to move more freely through the vitreous humour.
Estonian: Happe lagundamisel muundub klaaskeha sültjast ollusest vedelikuks, mis võimaldab rakkudel vabamalt läbi klaaskeha liikuda.
English: The main measure of effectiveness was the improvement in vision three months after the injection, assessed using a standard letter chart.
Estonian: Efektiivsust mõõdeti põhiliselt nägemises kolm kuud pärast süsti toimunud muutuse järgi, kasutades hindamiseks tavapärast silmade kontrolli tabelit.
English: This was expected to allow phagocytes (specialised ‘scavenger' cells of the immune system) to clear away any blood clots from the vitreous humour.
Estonian: See pidi võimaldama fagotsüütidel (immuunsüsteemi spetsiaalsed õgirakud) puhastada klaaskeha vereklompidest.
English: What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Vitragan?
Estonian: Millised on taotluse tagasivõtmise tagajärjed praegu Vitragani kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Vitragan had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Estonian: Seepärast oli inimtervishoius kasutatavate ravimite komitee tagasivõtmise ajal seisukohal, et Vitragani kasulikkust ei olnud piisavalt tõendatud ning et see ei olnud suurem väljaselgitatud riskidest.
English: The company informed the CHMP that there are currently no clinical trials or compassionate use programmes with Vitragan.
Estonian: Ettevõte teatas inimtervishoius kasutatavate ravimite komiteele, et praegu ei viida läbi ühtegi Vitragani kliinilist uuringut ega eriloaga kasutamise programmi.
English: Vitragan is a powder containing the active substance hyaluronidase (ovine).
Estonian: Vitragan on pulber, mis sisaldab toimeainena (lamba) hüaluronidaasi.
English: The CHMP had concerns over the benefits of Vitragan, since the main studies had not shown convincingly that it was more effective than available options for managing vitreous haemorrhage.
Estonian: Inimtervishoius kasutatavate ravimite komitee oli Vitragani kasulikkuse suhtes kahtleval seisukohal, sest põhiuuringud ei olnud veenvalt tõestanud selle suuremat efektiivsust võrreldes kättesaadavate ravimitega klaaskeha veritsemise vastu.
English: Vitragan was expected to be used to treat vitreous haemorrhage (bleeding into the vitreous humour, the jelly-like fluid in the central chamber of the eye) in adults.
Estonian: Vitragani kavandatud näidustuseks oli klaaskeha veritsemise (verejooks silma klaaskehasse, mis on sültjas vedelik silma keskses kambris) raviks täiskasvanutel.
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for VITRAGAN
Estonian: TEAVE MÜÜGILOA TAOTLUSE TAGASIVÕTMISE KOHTA VITRAGAN
English: The effects of Vitragan were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Vitragani toimet muude katsetega.
English: Ref. EMEA/195786/2007
Estonian: London, 24. mai 2007 Dokumendi nr EMEA/253850/2007
English: The active substance in Vitragan, hyaluronidase (ovine), is an enzyme extracted from sheep.
Estonian: Vitraganis toimeainena sisalduv (lamba) hüaluronidaas on lambalihast eraldatav ensüüm.
English: It was to be made up into a solution for injection into the eye.
Estonian: Sellest kavatseti valmistada silma süstimiseks mõeldud lahus.
English: What was Vitragan expected to be used for?
Estonian: Milleks kavatseti Vitragani kasutada?
English: How is Vitragan expected to work?
Estonian: Milline on Vitragani eeldatav toime?
English: It is expected to work by breaking down a molecule in the vitreous humour called hyaluronic acid.
Estonian: Selle eeldatav toime seisneb hüaluroonhappe molekuli lagundamises klaaskehas.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Vitragan could not have been approved for the treatment of vitreous haemorrhage.
Estonian: tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et Vitragani kasutamist klaaskeha veritsemisega patsientide raviks ei ole võimalik heaks kiita.
English: Your doctor will advise you what to do.
Estonian: Arst annab teile nõu, mida teha.
English: Day 5, Day 14 and Day 28
Estonian: 5., 14. ja 28. päev
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 17 June 2011
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 17 juuni 2011
English: Unopened vials 3 years
Estonian: Avamata viaalid 3 aastat
English: Patients with high PRA often require increased immunosuppression.
Estonian: Kõrge PRA patsiendid vajavad sageli suuremat immunosupressiooni.
English: The clinical relevance of such antibodies is unclear.
Estonian: Nimetatud antikehade kliiniline tähendus on ebaselge.
English: You might get symptoms that you might not be aware of yourself.
Estonian: Teil võivad tekkida sümptomid, mida te ei pruugi ise märgata.
English: The safety and efficacy of belatacept in children and adolescents 0 to 18 years of age have not yet been established.
Estonian: Belatatsepti ohutus ja efektiivsus lastel ja noorukitel vanuses 0 kuni 18 aastat pole veel tõestatud.
English: Study 2: extended criteria donors
Estonian: 2. uuring: laiendatud kriteeriumitele vastavad doonorid
English: This medicine will be stored in the healthcare facility where it is administered.
Estonian: Seda ravimit hoitakse tervishoiuasutuses, kus seda ka manustatakse.
English: Dublin 15 - Ireland
Estonian: Dublin 15 - Iirimaa
English: Studies in adult mice and monkeys have not demonstrated similar findings.
Estonian: Täiskasvanud hiirtel ja ahvidel teostatud uuringud sarnaseid tulemusi ei andnud.
English: Day of transplantation, prior to implantation (Day 1)
Estonian: Siirdamispäev, enne implantatsiooni (1. päev)
English: Your doctor will advise you about using a reliable contraceptive.
Estonian: Teie arst soovitab teile usaldusväärset rasestumisvastast vahendit.
English: UNIQUE IDENTIFIER - HUMAN READABLE DATA
Estonian: AINULAADNE IDENTIFIKAATOR - INIMLOETAVAD ANDMED.
English: Up to Year 3*,**
Estonian: Kuni kolmeaastane ravi*,**
English: * See section “Description of selected adverse reactions”.
Estonian: * Vt lõik „Valitud kõrvaltoimete kirjeldus“.
English: Please take the exact steroid dose as determined by your doctor.
Estonian: Palun kasutage arsti poolt määratud täpset steroidi annust.
English: The distribution of the card will also prompt dialogue on any new or changes in symptoms since the prior visit.
Estonian: Kaartide jaotamine tagab ka kiire teabevahetuse kas uute sümptomite või nende muudatuse kohta alates eelmisest visiidist.
English: NULOJIX has not been studied in children and adolescents under 18 years of age, therefore it is not recommended in this age group.
Estonian: NULOJIXit ei ole alla 18-aastastel lastel ja noorukitel uuritud, mistõttu ei ole seda selles vanuserühmas soovitatav kasutada.
English: Each pack of the medicine contains an alert card that should be given to the patient.
Estonian: Igas ravimipakendis on infokaart, mis tuleb anda patsiendile.
English: Start (Day of Transplant):_______________ Most recent: _________________________ Next treatment date:____________________ Patient's Name:_______________________ Doctor's Name:_______________________ Doctor's Phone:_______________________ If NULOJIX is stopped, keep this card with you for an additional 3 months.
Estonian: Järgmine manustamispäev:_____________________ Patsiendi nimi:_______________________ Arsti nimi:__________________________ Arsti telefon:________________________ Kui ravi NULOJIXiga lõpetatakse, kandke seda kaarti veel kolm kuud endaga kaasas.
English: Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving or operating machines.
Estonian: Patsiente tuleb informeerida, et nimetatud sümptomite tekkimise korral peavad nad hoiduma potentsiaalselt ohtlikest tegevustest nagu autojuhtimine ja masinatega töötamine.
English: ** Includes all events reported over a median of 3.3 years in the Phase 3 studies, and a median of approximately 7 years in the Phase 2 study.
Estonian: ** hõlmab kõiki juhte, mis registreeriti III faasi uuringutes keskmiselt 3,3 aasta jooksul ja II faasi uuringutes keskmiselt umbes 7 aasta jooksul.
English: The card will have your doctor's name and phone number and the date when you started treatment, your last treatment visit, and your next visit for treatment.
Estonian: Kaardil on kirjas teie arsti nimi ja telefoninumber ning ravi alustamise kuupäev, teie viimase ravivisiidi ja järgmise visiidi kuupäev.
English: Other medicines and NULOJIX
Estonian: Muud ravimid ja NULOJIX
English: Belatacept should not be used in pregnant women unless clearly necessary.
Estonian: Belatatsepti ei tohi rasedatel naistel kasutada, kui see ei ole hädavajalik.
English: These are medicines that reduce the activity of the immune system, the body's natural defences.
Estonian: Need on ravimid, mis vähendavad immuunsüsteemi, organismi loomuliku kaitsemehhanismi aktiivsust.
English: Belatacept has not been studied in patients with Panel Reactive Antibody (PRA) > 30% (who often require increased immunosuppression).
Estonian: Belatatsepti kasutamist ei ole uuritud patsientidel, kellel on reaktiivsete antikehade paneel (Panel Reactive Antibody, PRA) > 30% (kes sageli vajavad suuremat immunosupressiooni).
English: If you are not sure if you have been infected with the virus before, ask your doctor.
Estonian: Kui te ei ole kindel, kas te olete olnud selle viirusega varem nakatunud, küsige oma arstilt.
English: Take all medicines as instructed by your doctor.
Estonian: Võtke kõiki ravimeid vastavalt arsti ettekirjutusele.
English: For a list of symptoms please see section 4, “Possible side effects”.
Estonian: Lugege sümptomite nimekirja lõigus 4, "Võimalikud kõrvaltoimed".
English: PML often leads to severe disability or death.
Estonian: See haigus põhjustab sageli rasket invaliidsust või surma.
English: From week 4 after transplant, you will receive treatment with NULOJIX every 4 weeks.
Estonian: Neli nädalat pärast siirdamist alustatakse teile NULOJIXi manustamist iga nelja nädala tagant.
English: Progressive multifocal leukoencephalopathy
Estonian: Progressiivne multifokaalne leukoentsefalopaatia
English: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Estonian: Teatage oma arstile või apteekrile, kui te kasutate või olete hiljuti kasutanud või kavatsete kasutada mis tahes muid ravimeid.
English: In general, antibody titers were low, not usually persistent, and often became undetectable with continued treatment.
Estonian: Üldiselt olid antikehade tiitrid madalad, tavaliselt ebapüsivad ja muutusid ravi jätkamisel sageli tuvastamatuks.
English: Contrada Fontana del Ceraso 03012 Anagni (FR) - Italy
Estonian: Contrada Fontana del Ceraso 03012 Anagni (FR) - Itaalia
English: UNIQUE IDENTIFIER - 2D BARCODE 2D barcode carrying the unique identifier included.
Estonian: AINULAADNE IDENTIFIKAATOR - 2D vöötkood Lisatud on 2D-vöötkood, mis sisaldab ainulaadset identifikaatorit
English: Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA28.
Estonian: Farmakoterapeutiline grupp: immunosupressandid, selektiivsed immunosupressandid, ATC-kood: L04AA28.
English: You are being treated with a potent medicine that suppresses the immune system.
Estonian: Teid ravitakse tugevatoimelise ravimiga, mis pärsib immuunsüsteemi.
English: However, NULOJIX can cause serious side effects that may need treatment.
Estonian: NULOJIX võib siiski põhjustada tõsiseid kõrvaltoimeid, mis võivad vajada ravi.
English: The accumulation index for belatacept at steady state is 1.1.
Estonian: Belatatsepti akumulatsiooniindeks püsiseisundis on 1,1.
English: NULOJIX weakens the body's ability to fight infections.
Estonian: NULOJIX nõrgendab organismi nakkustega võitlemise võimet.
English: Use with other immunosuppressive medicines
Estonian: Kasutamine koos teiste immunosupressantidega
English: No pattern was identified in the causes of death.
Estonian: Surmapõhjuste osas kindlat mustrit kindlaks ei tehtud.
English: Do not use NULOJIX if you are pregnant unless your doctor specifically recommends it.
Estonian: Ärge kasutage NULOJIXit, kui te olete rase, kui arst ei ole seda spetsiaalselt soovitanud.
English: The majority of cases of tuberculosis occurred in patients who currently live or previously lived in countries with a high prevalence of tuberculosis.
Estonian: Enamus tuberkuloosijuhte esines patsientidel, kes praegu elavad või on varem elanud riikides, kus tuberkuloosi esinemissagedus on kõrge.
English: Immunosuppressant therapy may affect response to vaccination.
Estonian: Immunosupressiivne ravi võib mõjutada reaktsiooni vaktsineerimisele.
English: The frequency categories are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100).
Estonian: Esinemissageduse kategooriad on järgmised: väga sage (≥ 1/10); sage (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100).
English: Contrada Fontana del Ceraso I-03012 Anagni-Frosinone Italy
Estonian: Contrada Fontana del Ceraso I-03012 Anagni-Frosinone Itaalia
English: Infusion-related reactions Anaphylaxis has been reported post marketing(see section 4.4).
Estonian: Infusiooniga seotud reaktsioonid Anaphylaxis has been reported post marketing(see section 4.4).
English: Therapeutic monitoring of belatacept is not required.
Estonian: Belatatsepti terapeutiline jälgimine ei ole vajalik.
English: Pneumocystis pneumonia prophylaxis is recommended for at least 6 months following transplantation.
Estonian: Pneumocystis pneumonia profülaktika on soovitatav vähemalt kuue kuu vältel pärast transplantatsiooni.
English: Please make sure you have this card with you at all times and a list of all your other medicines with you at any visit to a healthcare professional.
Estonian: Palun veenduge, et teil on see kaart alati kaasas ja et te võtate arsti juurde minnes alati kaasa oma teiste ravimite nimekirja.
English: It is also recommended to administer an interleukin(IL)-2 receptor antagonist during the first week after transplantation.
Estonian: Samuti on soovitatav manustada interleukiin-2 (IL-2) retseptori antagonisti esimese nädala jooksul pärast siirdamist.
English: NULOJIX should not be used with siliconised syringes in order to avoid aggregate formation (see section 6.6).
Estonian: NULOJIXit ei tohi manustada silikoniseeritud süstaldega, et vältida agregaatide teket (vt lõik 6.6).
English: The diluted solution must be administered as an intravenous infusion at a relatively constant rate over 30 minutes.
Estonian: Lahjendatud lahus tuleb manustada intravenoosse infusioonina suhteliselt ühtlase kiirusega 30 minuti vältel.
English: Tell your doctor immediately if you or your family notice any symptoms listed below:
Estonian: Rääkige sellest kohe oma arstile, kui te märkate või teie perekond märkab teil mis tahes alljärgnevat sümptomit: